3782-10-3Relevant academic research and scientific papers
TBAI/TBHP mediated oxidative cross coupling of ketones with phenols and carboxylic acids: Direct access to benzofurans
Santhosh Kumar,Ravikumar,Chinna Ashalu,Rajender Reddy
supporting information, p. 33 - 37 (2017/12/11)
TBAI/TBHP mediated oxidative cross coupling of phenols and carboxylic acids with ketones has been reported under metal-free, base free, solvent free conditions enabling environmentally benign synthesis of aryloxyketones, acyloxy ketones and benzofurans. Phenoxyketones and acyloxylcarbonyl compounds were synthesized in good to high yields, where as benzofurans were synthesized in moderate yields. This method is operationally simple, works under mild conditions, using commercially available as well as inexpensive TBAI and an oxidant TBHP.
Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death
Magalhaes Moreira, Diogo Rodrigo,De Oliveira, Ana Daura Travassos,Teixeira De Moraes Gomes, Paulo André,De Simone, Carlos Alberto,Villela, Filipe Silva,Ferreira, Rafaela Salgado,Da Silva, Aline Caroline,Dos Santos, Thiago André Ramos,Brelaz De Castro, Maria Carolina Accioly,Pereira, Valéria Rego Alves,Leite, Ana Cristina Lima
, p. 467 - 478 (2014/03/21)
Chagas disease, caused by Trypanosoma cruzi, is a life-threatening infection leading to approximately 12,000 deaths per year. T. cruzi is susceptible to thiosemicarbazones, making this class of compounds appealing for drug development. Previously, the hom
SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
-
Page/Page column 21-23, (2010/11/03)
This invention relates to novel substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as modulators of potassium channels. In other aspects the invention relates to the use of these compounds, in a method for therapy and to pharmaceutical compositio
Multicyclic bis-amide MMP inhibitors
-
Page/Page column 101-102, (2008/06/13)
The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.
